Suzanne L. Topalian, MD; F. Stephen Hodi, MD; Julie R. Brahmer, MD; et al.
open access
has audio
JAMA Oncol. 2019;5(10):1411-1420. doi:10.1001/jamaoncol.2019.2187
This secondary analysis of the phase 1 CA209-003 clinical trial assesses the 5-year survival and other related factors among patients with advanced melanoma, renal cell carcinoma, or non鈥搒mall cell lung cancer receiving nivolumab.
-
Podcast:
Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab
Kenneth L. Kehl, MD, MPH; Haitham Elmarakeby, PhD; Mizuki Nishino, MD, MPH; et al.
free access
JAMA Oncol. 2019;5(10):1421-1429. doi:10.1001/jamaoncol.2019.1800
This cohort study examines the use of deep natural language processing in extraction of information on cancer outcomes from the medical records of patients with lung cancer.
-
Invited Commentary
The Tipping Point for Deep Learning in Oncology
Andrew Daniel Trister, MD, PhD
JAMA Oncol
Eileen M. O鈥橰eilly, MD; Do-Youn Oh, MD, PhD; Neesha Dhani, MD, PhD, FRCPC; et al.
free access
JAMA Oncol. 2019;5(10):1431-1438. doi:10.1001/jamaoncol.2019.1588
This phase 2 randomized clinical trial assesses the safety and efficacy of durvalumab鈥墂ith and without tremelimumab for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.
Guillaume Assié, MD, PhD; Anne Jouinot, MD; Martin Fassnacht, MD, PhD; et al.
free access
JAMA Oncol. 2019;5(10):1440-1447. doi:10.1001/jamaoncol.2019.1558
This biomarker analyss of patients with adrenocortical carcinoma compares the molecular classification for prognostic assessment of adrenocortical carcinoma with other known prognostic factors.
Thomas E. Stinchcombe, MD; Pasi A. Jänne, MD, PhD; Xiaofei Wang, PhD; et al.
free access
JAMA Oncol. 2019;5(10):1448-1455. doi:10.1001/jamaoncol.2019.1847
This phase 2 multicenter randomized clinical trial including 88 patients compares progression-free survival, and secondarily overall survival, overall response rate, and adverse events, in patients with stage 4 EGFR-mutant non鈥搒mall cell lung cancer treated with erlotinib plus bevacizumab vs erlotinib alone.
Pia Banerjee, PhD; Michael G. Rossi, DO; Doralina L. Anghelescu, MD; et al.
free access
JAMA Oncol. 2019;5(10):1456-1463. doi:10.1001/jamaoncol.2019.1094
This cohort study examines the neurocognitive and neuroimaging outcomes associated with multiple use of general anesthesia in survivors of childhood acute lymphoblastic leukemia.
Ramesh Rengan, MD, PhD; Rosemarie Mick, MS; Daniel A. Pryma, MD; et al.
free access
JAMA Oncol. 2019;5(10):1464-1472. doi:10.1001/jamaoncol.2019.2095
This phase 1/2 trial evaluates the toxic effects, maximally tolerated dose, and recommended phase 2 dose of the protease inhibitor nelfinavir administered concurrently with chemoradiotherapy for locally advanced non鈥搒mall cell lung cancer, and estimates the objective response rate, local and distant failure rates, and overall and progression-free survival.
Jonathan M. Loree, MD; Seerat Anand, MBBS; Arvind Dasari, MD; et al.
free access
online only
JAMA Oncol. 2019;5(10):e191870. doi:10.1001/jamaoncol.2019.1870
This database study assesses the frequency of race reporting and proportional race representation in trials that support FDA oncology drug approvals.
Nina N. Sanford, MD; Miranda B. Lam, MD, MBA; Santino S. Butler, MS; et al.
free access
online only
JAMA Oncol. 2019;5(10):e191973. doi:10.1001/jamaoncol.2019.1973
This survey study analyzes NHIS data from nearly 18鈥�000 patients with a cancer diagnosis before and after implementation of the Affordable Care Act (ACA) to evaluate patterns and patient-reported reasons for not having health insurance before and after the ACA.